RECURRENT PLATINUM-RESISTANT EPITHELIAL OVARIAN CANCER
Clinical trials for RECURRENT PLATINUM-RESISTANT EPITHELIAL OVARIAN CANCER explained in plain language.
Never miss a new study
Get alerted when new RECURRENT PLATINUM-RESISTANT EPITHELIAL OVARIAN CANCER trials appear
Sign up with your email to follow new studies for RECURRENT PLATINUM-RESISTANT EPITHELIAL OVARIAN CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo aims to unleash immune system against tough ovarian cancer
Disease control OngoingThis study tests whether a two-drug combination can help the immune system attack ovarian cancer that has returned after standard treatments. The drugs are E7777, which removes certain immune cells that block the body's defenses, and pembrolizumab, which reactivates cancer-fighti…
Matched conditions: RECURRENT PLATINUM-RESISTANT EPITHELIAL OVARIAN CANCER
Phase: PHASE1, PHASE2 • Sponsor: Alexander B Olawaiye, MD • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New triple therapy targets hard-to-treat ovarian cancer
Disease control OngoingThis study tests a combination of three drugs—ALX148, liposomal doxorubicin, and pembrolizumab—in people with recurrent ovarian cancer that no longer responds to platinum-based chemotherapy. The goal is to see if blocking the CD47 protein on cancer cells can boost the immune syst…
Matched conditions: RECURRENT PLATINUM-RESISTANT EPITHELIAL OVARIAN CANCER
Phase: PHASE2 • Sponsor: Alexander B Olawaiye, MD • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC